EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients
According to a recent World Health Organization estimate, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, which originated in China in 2019, has spread globally, infecting nearly 100 million people worldwide by January 2021. Patients with chronic liver diseases (CLD), particularly cirrhosis, hepatobiliary malignancies, candidates for liver transplantation, and immunosuppressed individuals after liver transplantation appear to be at increased risk of infections in general, which in turn translates into increased mortality.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Markus Cornberg, Maria Buti, Christiane S. Eberhardt, Paolo Antonio Grossi, Daniel Shouval Tags: Position Paper Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | China Health | Cirrhosis | Coronavirus | COVID-19 | Gastroenterology | International Medicine & Public Health | Liver | Liver Disease | Liver Transplant | Pandemics | Respiratory Medicine | SARS | Transplant Surgery | Transplants | Urology & Nephrology | Vaccines | WHO